Market Closed

DSGN
Design Therapeutics
$ 10.47
-1.04%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago

Design Therapeutics News

Latest Design Therapeutics Stock News & DSGN Headlines

Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027
a month ago | seekingalpha.com
Design Therapeutics, Inc. (NASDAQ:DSGN) Stock Now Rated “Moderate Buy” by Sell-Side Analysts
2 months ago | defenseworld.net
Bank of New York Mellon Corp Purchases New Stake in Design Therapeutics, Inc. $DSGN
2 months ago | defenseworld.net
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
3 months ago | globenewswire.com
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
5 months ago | globenewswire.com
Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts
5 months ago | seekingalpha.com
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
6 months ago | globenewswire.com
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
6 months ago | benzinga.com
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
6 months ago | seekingalpha.com
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
6 months ago | globenewswire.com
Load More

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

oinCodex Android App
CoinCodex Mobile App
Market Closed

DSGN
Design Therapeutics
$ 10.47
-1.04%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago